三金药业品牌怎么样 申请店铺

我要投票 三金药业在牙粉行业中的票数:663 更新时间:2025-12-16
三金药业是哪个国家的品牌?「三金药业」是 桂林三金药业股份有限公司 旗下著名品牌。该品牌发源于广西,由创始人邹节明在1994期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力三金药业品牌出海!将品牌入驻外推网,定制三金药业品牌推广信息,可以显著提高三金药业产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

三金药业怎么样

桂林三金药业股份有限公司是三金集团的核心企业,主营中成药、天然药物的研发和生产,是国内最早生产现代中药制剂的厂家之一。1985年以来,桂林三金坚持改革创新,依靠科技进步和科学管理,主要经济指标以30%左右的年均速度递增,2009年,公司实现营业收入11.10亿元、利润总额3.77亿元,均同比增长10%以上,主要经济指标连续多年居广西医药行业首位,并位列中国中药行业50强前列,曾先后荣获全国质量效益型先进企业、全国企业管理杰出贡献奖、全国“五一”劳动奖状、全国思想政治工作优秀企业、全国文明单位、全国中药行业优秀企业等荣誉。

中药是国粹,作为地道的广西药企和传统产业中的一员,三金在崛起之初,就确立了“继承不泥古,发扬不离宗”的研发方向,并坚持以中医药理论为指导,现代科技为手段,依托广西本地资源,摒弃低水平仿制的老路,自主创新独家特色产品,创自己的名牌。目前,三金已成为区内外知名的高新技术企业,创新体系完备,研发投入充足,研发实力强劲,拥有国家级技术中心和博士后科研工作站,公司现有特色中药新药基本均由企业技术中心为主导研制,拥有自主知识产权,获国家中药发明专利或国家中药保护品种20余项。目前,三金在咽喉、口腔用药和泌尿系统用药方面已形成较强的专业和市场优势,代表产品三金西瓜霜系列、三金片成为全国同类中药的第一品牌,“三金”牌商标被国家工商行政总局认定为“驰名保护”,“三金”牌产品已行销海内外,并享有良好声誉。

多年来,三金一直坚持以产品经营为主,资本经营为辅的策略,在管理上,坚持推行“哑铃型”管理模式,不断引入国际、国内同行业的高标准,积极提高企业整体素质;目前,公司及下属药业类子公司已全面通过国家FSDA的GMP认证,企业竞争实力得到进一步增强。

目前,三金已成功进入国内资本市场,并积极响应桂林市委、市政府“向西发展,再造一个新桂林”的号召,开始了再创业的新征程,面向未来,我们将继续秉承“泽及生命、关爱健康、药精济世、忠实科学”的宗旨,因企制宜,不断创新,将三金建成国内领先、世界一流的中成药、天然药物研发生产企业,积极推动中药产业现代化与国际化,并有效提升对地方经济的贡献率,拉动相关产业发展。

Guilin Sanjin Pharmaceutical Co., Ltd. is the core enterprise of Sanjin group, which is mainly engaged in the research and development and production of Chinese patent medicine and natural medicine. It is one of the earliest manufacturers of modern Chinese medicine preparations in China. Since 1985, Guilin Sanjin has been insisting on reform and innovation, relying on scientific and technological progress and scientific management, and its main economic indicators have increased at an average annual rate of about 30%. In 2009, the company achieved an operating revenue of 1.11 billion yuan and a total profit of 377 million yuan, with a year-on-year growth of more than 10%. Its main economic indicators have ranked the first in Guangxi's pharmaceutical industry for many years in a row, and ranked among the top 50 Chinese medicine industries It has won the honors of national advanced enterprise of quality and benefit, national outstanding contribution award of enterprise management, national "May 1st" labor certificate, national excellent enterprise of Ideological and political work, national civilized unit, national excellent enterprise of traditional Chinese medicine industry, etc. Traditional Chinese medicine is the quintessence of the country. As one of the authentic pharmaceutical enterprises and traditional industries in Guangxi, Sanjin established the research and development direction of "inheriting the ancient and developing the ancient", and insisted on taking the theory of traditional Chinese medicine as the guidance, modern technology as the means, relying on the local resources of Guangxi, abandoning the old way of low-level imitation, innovating the exclusive characteristic products independently and creating its own brand. At present, Sanjin has become a well-known high-tech enterprise inside and outside the District, with complete innovation system, sufficient R & D investment and strong R & D strength. It has a national technology center and postdoctoral research workstation. The company's existing characteristic new Chinese medicine is basically guided by the enterprise technology center, with independent intellectual property rights, and has won more than 20 national invention patents or national protected varieties of Chinese medicine Item. At present, Sanjin has formed strong professional and market advantages in throat, oral medicine and urinary system medicine. Sanjin watermelon cream series and Sanjin tablet, the representative products, have become the first brand of the same kind of traditional Chinese medicine in China. The trademark of Sanjin is recognized as "well-known protection" by the State Administration for Industry and commerce. Sanjin brand products have been sold at home and abroad and enjoy a good reputation. Over the years, Sanjin has been adhering to the strategy of focusing on product management and complementing capital management. In terms of management, Sanjin adheres to the management mode of "dumbbell type", constantly introduces high standards of the same industry at home and abroad, and actively improves the overall quality of the enterprise. At present, the company and its pharmaceutical subsidiaries have fully passed the GMP certification of the national fsda, and the competitiveness of the enterprise has been further enhanced. At present, Sanjin has successfully entered the domestic capital market, and actively responded to the call of Guilin municipal Party committee and municipal government to "develop to the West and create a new Guilin", started a new journey of re entrepreneurship. Facing the future, we will continue to adhere to the tenet of "benefiting life, caring for health, medicine, economy, and science", and build Sanjin into a leading position in China due to enterprise conditions and continuous innovation The world-class R & D and production enterprises of traditional Chinese medicine and natural medicine actively promote the modernization and internationalization of traditional Chinese medicine industry, effectively improve the contribution rate to local economy, and promote the development of related industries.

本文链接: https://brand.waitui.com/a7171ed71.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

牙粉行业十大品牌
牙粉行业排行榜第1名 | 三金药业
三金药业
663
牙粉行业排行榜第2名 | 皓齿健
皓齿健
600
外推网广告位招租,每天只要9块9

7×24h 快讯

华泰证券:明年主网设备的紧缺和传统电源设备出海将带来差异化投资机会

36氪获悉,华泰证券指出,我们认为虽然短期能源结构会因新能源系统瓶颈呈现周期属性,但是最终新能源制造业属性和对资源低依赖,必然使得未来系统实现平价,产业将会再次出现非线性增长。我们认为全球电力基建紧张的大背景下,传统电气设备(电网电源)的重估市场仍然认识不足,且存在较多估值洼地,明年主网设备的紧缺和传统电源设备出海将带来差异化投资机会。

2小时前

密集增资扩股,商业银行年底加快“补血”

年末将至,商业银行新一轮增资热潮加速袭来。记者发现,近来,包括建设银行、中国银行、苏州银行、湖南银行、长安银行等在内的多家商业银行纷纷采取增资举措。对此,业内专家表示,商业银行被增持,既是应对监管要求、夯实“安全垫”的主动选择,也是加力支持实体经济、提升服务质效的必然措施。随着相关政策的落地和市场预期的修复,银行板块正加快迎来估值重构。(经济参考报)

2小时前

中信证券:年内外贸出口基本面仍有支撑

36氪获悉,中信证券研报认为,展望后续,我们判断年内外贸出口基本面仍有支撑,固定资产投资在政策性金融工具和增量地方债额度等政策发力的带动下有望温和改善,但12月消费温度可能仍然偏低。12月中央经济工作会议在北京举行,要求继续实施更加积极的财政政策和适度宽松的货币政策,并指出“发挥存量政策和增量政策集成效应”,我们认为政策或更注重政策协调与落地效果,增强经济高质量发展动力活力。

2小时前

中信证券:看好美股软件板块中期投资机会

36氪获悉,中信证券研报认为,三季度以来,美股软件板块表现较为疲软,其中应用软件尤为明显。三季报显示,板块需求环境趋于稳定,企业业绩及指引超预期比例亦进一步上升。同时预计后续“降息+宽财政”的组合将持续推动欧美企业软件支出的回暖,而经历自2024Q4以来的准备、测试之后,AI+软件货币化效果亦有望在2026年逐步落地。当前时点,我们看好美股软件板块中期投资机会,建议关注:低位企稳回升的应用软件,以及持续高景气度的信息安全(平台化)、基础软件(数据管理方向)。

2小时前

英伟达收购开源工作负载管理提供商SchedMD

当地时间12月15日,英伟达宣布收购开源工作负载管理提供商SchedMD。英伟达表示,将继续开发和分发开源工作负载管理系统Slurm,使其能够被更广泛的HPC和AI社区在各种硬件和软件环境中广泛使用并获得支持。(界面)

2小时前

本页详细列出关于三金药业的品牌信息,含品牌所属公司介绍,三金药业所处行业的品牌地位及优势。
咨询